13 search results
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
Cochrane EvidencePublished 30 Jun 2014
Androgen suppression monotherapy for treatment of advanced prostate cancer
Review question We reviewed the evidence on the effects of androgen suppression monotherapies (non-steroidal antiandrogens compared with medical or surgical castration monotherapy) in men with advanced prostate cancer. Background Prostate cancer is among the top six most lethal cancers, and treatment implies a high disease burden for patients. An ... -
Cochrane EvidencePublished 24 Dec 2013
Psychosocial interventions for men with prostate cancer
Approximately one in six men will be diagnosed with prostate cancer in their lifetime, and the number of men living with, or after, the diagnosis will continue to rise. Some of them will experience problems such as difficulty in passing urine, pain and sexual dysfunction, and these may cause distress, anxiety, uncertainty or depression. Their quality ... -
Cochrane EvidencePublished 31 Jan 2013
Screening for prostate cancer
Prostate cancer is one of the most prevalent forms of cancer in men worldwide. Screening for prostate cancer implies that diagnostic tests be performed in the absence of any symptoms or indications of disease. These tests include the digital rectal examination (DRE), the prostate-specific antigen (PSA) blood test and transrectal ultrasound (TRUS) guided ... -
Cochrane EvidencePublished 9 Nov 2011
Lycopene for the prevention of prostate cancer
Prostate cancer is a common form of cancer affecting men worldwide. Pharmaceutical interventions, such as 5-alpha reductase inhibitors, have been identified as potentially preventing prostate cancer incidence in men. Many men modify lifestyle and consume complementary and alternative medicines to maintain better health and prevent disease. Lycopene ... -
Cochrane EvidencePublished 6 Jul 2011
Low-dose rate brachytherapy for men with localized prostate cancer
Localized prostate cancer has not spread outside the prostate gland. LDR-BT is short-distance internal radiotherapy. Low-energy radioactive sources with a short half-life are implanted permanently into the prostate. We reviewed the published research on this treatment to investigate how effective and safe it is. Unfortunately, we identified only one ... -
Cochrane EvidencePublished 11 May 2011
Antibiotic prophylaxis for transrectal prostate biopsy
Prostate cancer is the second most commonly diagnosed cancer in men and transrectal prostate biopsy is the procedure to obtain tissue for the histological diagnosis of carcinoma of the prostate. Despite the fact that infective complications after transrectal prostate biopsy are well known, there is uncertainty about the necessity and effectiveness of ... -
Cochrane EvidencePublished 10 Nov 2010
Radical prostatectomy (RP) versus watchful waiting (WW) for the treatment of localized prostate cancer: a review of the evidence
In this review the best available evidence comparing the effects of two treatment options for localised prostate cancer, namely radical prostatectomy (RP) which involves surgically removing the prostate gland versus a "watchful waiting" (WW) approach was examined. In this review, WW is defined as any conservative approach to the management of prostate ... -
Cochrane EvidencePublished 17 Oct 2007
To evaluate the effectiveness and safety of intermittent androgen suppression compared to continuous androgen suppression for treating prostatic cancer.
After lung cancer, prostate cancer is the most common cause of death among males. The American Cancer Society estimates that 234,460 new cases of prostate cancer were diagnosed, and 27,350 men died from this disease in the United States in 2006 (ACS 2006). Treatment for early stage prostate cancer that is believed to be confined to the prostate gland ... -
Cochrane EvidencePublished 18 Jul 2007
Cryotherapy for localised prostate cancer
Cryotherapy is a relatively new procedure for the treatment of localised prostate cancer. Under anaesthesia, probes are inserted into the prostate tumour that freeze the tissue, thereby killing tumour cells. This procedure is carried out on a day-patient basis and generally patients are allowed home the following day. The main complications associated ... -
Cochrane EvidencePublished 18 Oct 2006
Bisphosphonates for advanced prostate cancer
Prostate cancer is the most common cancer in men in many western countries and is characterized by its propensity to spread to bone which occurs in more than 80% of patients with advanced disease. Patients are at risk of complications including pain, hypercalcaemia, bone fracture and spinal cord compression. The role of bisphosphonates for the palliation ...
